查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553520

肝癌藥物市場規模、佔有率和趨勢分析報告：按藥物、類型、分銷管道、地區和細分市場趨勢：2024-2030

Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug (Targeted Therapy, Immunotherapy, Chemotherapy), By Type, By Distribution Channel, By Region And Segment Forecasts 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

肝癌藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年全球肝癌藥物市場規模將達到98.1億美元，2024年至2030年複合年成長率為17.8%。

肝癌市場的成長很大程度上取決於新藥的供應、強大的產品線的存在以及公眾意識的提高等因素。肝癌患者數量的增加是由於不健康的生活方式和人口老化的增加所造成的。這有利於肝癌藥物市場。針對不能耐受多吉美患者的二線治療藥物的開發預計將對肝癌領域產生重大影響。

肝癌是全球第五大常見癌症，佔癌症死亡人數的 9.0%。 2012年，新診斷肝癌人數為782,451人，死於肝癌的人數為745,533人。由於其高度侵襲性和低存活率，原發性肝癌仍然是一個重要的公共衛生問題。肝細胞癌佔原發性肝癌的大部分（75-90%）。肝癌的許多顯著原因，包括肝炎感染和肝硬化，都是可以改變的，生活方式改變和肝炎疫苗接種等預防策略為降低肝癌的發病率和死亡率提供了廣闊的前景。

肝癌藥物市場報告亮點

  • 由於標靶治療涉及癌細胞生長和擴散的特定分子或途徑的高精度，標靶治療治療領域在 2023 年佔據最大的市場收益佔有率，為 53.0%。
  • 肝細胞癌（HCC）在肝癌藥物市場中佔據主導地位，2023 年收益佔有率為 36.6%。肝細胞癌是最常見的原發性肝癌類型。
  • 醫院藥屋主導肝癌藥物市場，2023年收益佔有率為45.5%。
  • 2023年北美肝癌藥物市場佔銷售量42.​​7%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章肝癌藥物市場的變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 肝癌藥物市場分析工具
    • 波特的分析
    • PESTEL分析

第4章肝癌藥物市場：按藥物分類的估計和趨勢分析

  • 細分儀表板
  • 肝癌藥物市場：2018-2030年藥物波動分析
  • 標靶治療
  • 免疫療法
  • 化療

第5章肝癌藥物市場：依類型估計及趨勢分析

  • 細分儀表板
  • 肝癌藥物市場：2018年及2030年類型變化分析
  • 肝細胞癌
  • 膽管癌
  • 肝母細胞瘤

第6章肝癌藥物市場：依通路估算與趨勢分析

  • 細分儀表板
  • 肝癌藥物市場：2018年及2030年通路變化分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章肝癌藥物市場：區域估計與趨勢分析

  • 2023 年及 2030 年肝癌藥物市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國。
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Merck KGaA
    • Exelixis, Inc.
    • Eisai Co., Ltd.
    • Bristol-Myers Squibb Company.
    • Bayer AG
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Eli Lilly and Company
    • Pfizer Inc.
簡介目錄
Product Code: GVR-2-68038-513-7

Liver Cancer Drug Market Growth & Trends:

The global liver cancer drug market size is expected to reach USD 9.81 billion by 2030, registering a CAGR of 17.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights:

  • The targeted therapy segment held the largest market revenue share of 53.0% in 2023 due to its precision in targeting specific molecules or pathways involved in the growth and spread of cancer cells.
  • Hepatocellular Carcinoma (HCC) dominated the liver cancer drug market with a 36.6% revenue share in 2023. HCC Is the most common type of primary liver cancer.
  • Hospital pharmacy dominated the liver cancer drug market with a revenue share of 45.5% in 2023.
  • North America liver cancer drug market held a revenue share of 42.7% in 2023.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Liver Cancer Drug Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Liver Cancer Drug Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Liver Cancer Drug Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Liver Cancer Drug Market: Drug Movement Analysis, 2018 - 2030 (USD Million)
  • 4.3. Targeted Therapy
    • 4.3.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1. Bevacizumab
        • 4.3.1.1.1. Bevacizumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2. Cabozantinib
        • 4.3.1.2.1. Cabozantinib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3. Lenvatinib
        • 4.3.1.3.1. Lenvatinib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.4. Ramucirumab
        • 4.3.1.4.1. Ramucirumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.5. Regorafenib
        • 4.3.1.5.1. Regorafenib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.6. Sorafenib
        • 4.3.1.6.1. Sorafenib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.7. Other Targeted Therapies
        • 4.3.1.7.1. Other Targeted Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Immunotherapy
    • 4.4.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.1. Atezolizumab with Bevacizumab
        • 4.4.1.1.1. Atezolizumab with Bevacizumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.2. Nivolumab with Ipilimumab
        • 4.4.1.2.1. Nivolumab with Ipilimumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.3. Pembrolizumab
        • 4.4.1.3.1. Pembrolizumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.4. Durvalumab with Tremelimumab
        • 4.4.1.4.1. Durvalumab with Tremelimumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.5. Other Immunotherapies
        • 4.4.1.5.1. Other Immunotherapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Chemotherapy
    • 4.5.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.1. Gemcitabine
        • 4.5.1.1.1. Gemcitabine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.2. Oxaliplatin
        • 4.5.1.2.1. Oxaliplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.3. Cisplatin
        • 4.5.1.3.1. Cisplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.4. Doxorubicin
        • 4.5.1.4.1. Doxorubicin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.5. 5-fluorouracil
        • 4.5.1.5.1. 5-fluorouracil Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.6. Capecitabine
        • 4.5.1.6.1. Capecitabine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.7. Mitoxantrone
        • 4.5.1.7.1. Mitoxantrone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.8. Other Chemotherapies
        • 4.5.1.8.1. Other Chemotherapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Liver Cancer Drug Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Liver Cancer Drug Market: Type Movement Analysis, 2018 & 2030 (USD Million)
  • 5.3. Hepatocellular Carcinoma
    • 5.3.1. Hepatocellular Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Cholangio Carcinoma
    • 5.4.1. Cholangio Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Hepatoblastoma
    • 5.5.1. Hepatoblastoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Liver Cancer Drug Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Liver Cancer Drug Market: Distribution Channel Movement Analysis, 2018 & 2030 (USD Million)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacy
    • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Liver Cancer Drug Market: Regional Estimates & Trend Analysis

  • 7.1. Liver Cancer Drug Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK.
      • 7.3.2.1. UK Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Merck KGaA
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Exelixis, Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Eisai Co., Ltd.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Bristol-Myers Squibb Company.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Bayer AG
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Novartis AG
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. F. Hoffmann-La Roche Ltd
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Eli Lilly and Company
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Pfizer Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives